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SLC6A4 METHYLATION MODIFIES THE EFFECT
OF THE NUMBER OF TRAUMATIC EVENTS ON RISK
FOR POSTTRAUMATIC STRESS DISORDER
Karestan C. Koenen, Ph.D.,1,3 Monica Uddin, Ph.D.,4 Shun-Chiao Chang, D.Sc.,1,2 Allison E. Aiello, Ph.D. M.S.,4
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Background: Posttraumatic stress disorder (PTSD) is a common and debilitating
mental disorder that occurs following exposure to a traumatic event. However, most
individuals do not develop PTSD following even a severe trauma, leading to a
search for new variables, such as genetic and other molecular variation, associated
with vulnerability and resilience in the face of trauma exposure. Method: We
examined whether serotonin transporter (SLC6A4) promoter genotype and
methylation status modified the association between number of traumatic events
experienced and PTSD in a subset of 100 individuals from the Detroit
Neighborhood Health Study. Results: Number of traumatic events was strongly
associated with risk of PTSD. Neither SLC6A4 genotype nor methylation status was
associated with PTSD in main effects models. However, SLC6A4 methylation levels
modified the effect of the number of traumatic events on PTSD after controlling for
SLC6A4 genotype. Persons with more traumatic events were at increased risk for
PTSD, but only at lower methylation levels. At higher methylation levels,
individuals with more traumatic events were protected from this disorder. This
interaction was observed whether the outcome was PTSD diagnosis, symptom
severity, or number of symptoms. Conclusions: Gene-specific methylation patterns
may offer potential molecular signatures of increased risk for and resilience to
PTSD. Depression and Anxiety 28:639–647, 2011. r 2011 Wiley-Liss, Inc.
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INTRODUCTION
Posttraumatic stress disorder (PTSD) occurs following
exposure to a traumatic event, and is characterized by
three symptom clusters: reexperiencing, avoidance and
numbing, and hyperarousal. PTSD is distinct from other
commonly occurring mental disorders, in that exposure
to a traumatic stressor is a prerequisite for diagnosis.
Although a majority[1] of adults in the United States have
been exposed to traumatic events, only a minority go
on to develop the disorder: lifetime rates of PTSD are
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estimated at approximately 6.8% and 12-month pre-
valence rates at approximately 3.5%.[2,3] Even among
individuals exposed to objectively high levels of trauma,
the conditional risk of PTSD is less than 50%.[1] The
contrast between the prevalence of trauma exposure and
the prevalence of PTSD has driven the search for risk
and protective factors—beyond burden of trauma
exposure—that influence vulnerability and resilience to
developing the disorder. However, the traditional risk
factor models supported by meta-analytic studies explain
only about 20% of the interpersonal variance in
PTSD.[4] The limitations of established risk factor
models has led to a search for new variables, such as
genetic and other molecular variation, associated with
vulnerability and resilience in the face of trauma
exposure.
The serotonin transporter (SLC6A4) locus has been
the most commonly studied gene in relation to PTSD.
The protein encoded by SLC6A4 serves many func-
tions; however, its action has been particularly well-
studied in the brain, where it transports serotonin at
synaptic terminals and other neuronal areas[5] and
serves to regulate emotional aspects of behavior.[6]
Previous work on SLC6A4 has examined whether DNA
sequence variation in this gene is associated with
PTSD diagnosis or symptoms. Of the 40 published
candidate gene association studies for PTSD, 9 have
focused on SLC6A4 and specifically on the commonly
occurring VNTR polymorphism found in the promo-
ter region (5-HTTLPR).[7] The alleles in the promoter
region of this gene have traditionally been classified as
short (s) and long (l), with the latter conferring higher
expression than the former[8] and the former being
associated with greater amygdala activity to fearful
stimuli.[9] Published findings for this locus and PTSD
have been somewhat contradictory, with six of the
nine studies finding the s-allele or s/s genotype
associated with elevated risk of PTSD diagnosis[10–14]
or symptoms,[15] two studies finding association
between the high expression variant and PTSD,[16,17]
and one study finding no evidence for an associa-
tion.[18] Importantly, four of the nine studies involving
this locus report evidence for a significant genotype
by environment interaction,[11,12,14,17] whereby the
effect of genotype on risk of PTSD was stronger
among individuals under high stress (versus low stress)
conditions. Taken together, these studies provide
evidence for the role of SLC6A4 in the etiology of
PTSD. However, the picture presented is complex, in
that the association seems to be modified by environ-
mental conditions and other factors.
The complexity of the association between SLC6A4
and PTSD may be related, in part, to emerging
evidence suggesting that methylation at CpG sites
(downstream of the 5-HTTLPR region) contributes
to SLC6A4 expression. DNA methylation is one of
the major mechanisms of epigenetic regulation or the
regulation of genetic functions mediated through
mechanisms that are independent of DNA sequences.
DNA methylation occurs in vertebrates predominantly
through covalent modification of DNA, whereby
methyl groups are coupled to cytosine residues when
cytosine and guanine are separated by a phosphate
(i.e. at a CpG site).[19] Methylation involves chemical
modifications that regulate DNA accessibility, which
in turn alters the transcriptional activity of the
surrounding loci. In many cases, increased methylation
in specific gene regions (e.g. promoter) is associated
with reduced transcriptional activity, and therefore
gene expression.
Work by Philbert et al. using samples from the Iowa
Adoption Studies cohort provided initial evidence that
increased methylation levels, in the CpG island over-
lapping with the transcriptional start site of SLC6A4,
was associated with decreased levels of SLC6A4 RNA,
and that those with the 5-HTTLPR s allele showed a
trend toward higher methylation levels across CpG
sites located in this upstream island.[20,21] This same
group showed that child abuse was associated with
significantly elevated methylation levels across multiple
CpG sites and, among females, at specific CpG sites as
well.[22] Taken together, these Iowa Adoption Study
results are suggestive of a relation between SLC6A4
methylation and stress-related outcomes. Nevertheless,
one limitation of these studies is the use of DNA
derived from EBV-transformed lymphoblast cell lines,
which have been demonstrated to undergo alterations
in methylation status with increasing cell passages.[23]
Studies of both SLC6A4 genotype and methylation
suggest that this gene may be salient to the develop-
ment of stress-related outcomes. This article examines
whether methylation status of the SLC6A4 gene
modifies the association between the number of
traumatic events and risk of PTSD. To address this,
we tested whether SLC6A4 genotype and methylation
levels were associated with PTSD and modified the
effect of the number of traumatic events on risk for
PTSD. Samples were drawn from 100 individuals in
the Detroit Neighborhood Health Study (DNHS),
using microarray-derived methylation data for two
CpG sites upstream of SLC6A4. The first CpG site
(cg05016953) occurs within a 799 bp CpG[24] island
that overlaps with the first exon of SLC6A4,[25]
upstream of the gene’s predicted transcription start
sites but downstream of the 5-HTTLPR VNTR
locus.[26] The second site (cg22584138) occurs within
the first intron of SLC6A4, upstream of the gene’s start
codon but downstream of the gene’s predicted start
sites, CpG island, and 5-HTTLPR locus.
MATERIALS AND METHODS
DETROIT NEIGHBORHOOD HEALTH STUDY
The DNHS is a study of adults, 18 years or older, from the Detroit
population. A probability sample of 1,547 households within the city
limits of Detroit was initially chosen and one individual per
household was then randomly selected for interview. Participants
were administered a 40 min assessment, which included questions on
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exposure to traumatic events, sociodemographic characteristics, and a
standardized assessment of PTSD and depression. The DNHS was
approved by the Institutional Review Board at the University of
Michigan.
Respondents were also asked to provide blood specimen by way of
venipuncture; 612 samples were collected from consenting parti-
cipants. We performed a two-tailed chi-square test to determine if
participants who provided a blood sample (n 5 612) were significantly
different from the total sample (n 5 1,547); results show that the
sociodemographic characteristics of the consenting participants of
the blood draw were comparable to the complete sample.
The sample for this study consisted of 100 of these 612 consenting
participants. Descriptive statistics for the sample are presented in
Table 1. We compared the 100 individuals in our final sample to the
612 consenting participants of the blood draw and found that the two
samples differ only on age—our final sample consisted of a slightly
higher proportion of younger individuals.
NUMBER OF TRAUMATIC EVENTS
Participants were initially asked to identify traumatic events that
they experienced from a list of 19. These included: military combat,
rape, other sexual assault, shot/stabbed, held captive/tortured/
kidnapped, mugged/held up/threatened with a weapon, badly beat
up, serious car or motor vehicle crash, any other kind of serious
accident or injury, fire, flood, earthquake or other natural disaster,
diagnosed with a life threatening illness, witnessed someone being
killed or seriously injured, unexpectedly discovering a dead body,
learning about a loved one being raped, seriously physically attacked,
seriously injured in a motor vehicle crash or in any other accident,
and sudden unexpected death of a close friend or relative. Number of
traumatic events was a count of the different types of trauma event
and ranged from 0–19 for each person.
ASSESSMENT OF POSTTRAUMATIC
STRESS DISORDER
Individual assessment of PTSD symptoms was conducted via
telephone interview using a modified version of the PTSD checklist,
a 17-item self-report measure of Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) symptoms, and additional questions
about duration, timing, and impairment or disability due to the
symptoms. PTSD symptoms were then assessed by referencing the
event that the participant regarded as the worst. Respondents were
considered affected by lifetime PTSD, if all six DSM-IV criteria were
met in reference to either of the worst event. All 100 individuals
included in this study were exposed to at least one traumatic event;
among these, 23 were PTSD affected and 77 were unaffected.
ASSESSMENT OF LIFETIME DEPRESSION
Individual assessment of lifetime depression was conducted using
a modified version of the Patient Health Questionnaire checklist,
a nine-item self-report measure based on the DSM-IV criteria.[27]
Each of the nine symptoms was scored from 0 (not at all) to 3 (nearly
every day). Depression was considered present when two or more
symptoms have been present at least ‘‘more than half the days’’ in
a 2-week period, and one of the symptoms is depressed mood or
anhedonia, and the respondent reported that the symptoms seem to
occur together. One symptom, ‘‘thoughts that you would be better off
dead or of hurting yourself in some way’’ counts if at all present,
regardless of frequency/duration.
VALIDATION OF POSTTRAUMATIC STRESS
DISORDER AND DEPRESSION
We assessed the validity of our identification of PTSD and
depression via in-person clinical interviews among a random
subsample of 51 participants.[28] As described previously, a trained
counselor conducted 1 hr in-person clinical interviews, using the
Clinician-Administered PTSD Scale for DSM-IV for PTSD[29] and
the Structured Clinical Interview for DSM-IV Disorders.[30] The
counselor was blinded to the information obtained from the main
study. Comparison of the clinical interviews with the main study
showed excellent concordance for both PTSD and depression.[28]
MICROARRAY ANALYSES
DNA was isolated from whole blood using the Qiagen
(Valencia, CA) QIAamps DNA Mini Kit. Bisulfite conversion of
whole blood-derived DNA samples was performed using the EZ-96
DNA methylation kit from Zymo Research (Orange, CA). One
microgram of each sample (including controls) was subjected to
TABLE 1. Descriptive statistics and bivariate comparisons of participants with and without PTSD
Trauma exposed/no
PTSD (n 5 77) PTSD (n 5 23)
Overall n/mean Sample %/SD n/mean %/SD n/mean %/SD Test P-value
SLC6A4 methylation b-value 0.35 0.13 0.35 0.13 0.33 0.12 .50
Number of traumatic events 6.04 3.6 5.58 3.48 7.57 3.65 .02
Age 45.32 16.78 44.91 17.29 46.70 15.19 .66
Female 60 60 45 58.4 15 65.2 .56
African-American 79 79 62 80.5 17 73.9 .56
Education equal to or greater than high school 86 86 67 87.01 19 82.61 .73
Ever smoke 58 58 41 53.3 17 73.9 .08
PBMC 23.34 8.05 23.35 8.31 23.29 7.25 .97
Depression diagnosis 33 33 21 27.30 12 52.20 .03
SLC6A4 genotype (functional classification)
SS, SLg, LgLg 21 21 17 22.10 4 17.40 .70
SLa, LgLa 46 46 33 42.9 13 56.5
LaLa 29 29 24 31.20 5 21.70
LaXL, LgXL 4 4 3 3.90 1 4.40
PBMC, peripheral blood mononuclear cells.
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bisulfite conversion following manufacturer’s recommended protocol.
Experimental controls included replicates for two samples to assess
variation throughout the experimental process (i.e. from initial
bisulfite conversion through microarray analysis), as well as one
sample of completely unmethylated and completely methylated
human DNA, commercially available through Zymo Research, in
each of the two 96 well plates used in the bisulfite conversion step.
All control replicates were placed on separate microarray chips, and
the remaining samples were assigned to microarray chips at random,
without regard to PTSD status. Bisulfite-converted DNA samples
were subjected to methylation profiling via the humanmethylation27
DNA Analysis BeadChip by Illumina following the manufacturer’s
recommended protocol. Using this platform, methylation levels were
determined for 27,578 CpG dinucleotides spanning 14,495 genes in
each of the 100 test samples. The resulting data were background
normalized using Bead Studio. Correlation coefficients of the two
replicated samples were .81 and .89, respectively. Methylation micro-
array data were initially validated via pyrosequencing and DNA
sequencing of a subset of individuals tested on the original
microarray, and are reported in detail elsewhere.[28]
Methylation of SLC6A4 was assessed at two CpG sites represented
on the HM27 beadchip. The first CpG site (cg05016953) occurs
within a 799 bp CpG[24] island that overlaps with the first exon of
SLC6A4,[25] upstream of the gene’s predicted transcription start sites
but downstream of the 5-HTTLPR VNTR locus.[26] The second site
(cg22584138) occurs within the first intron of SLC6A4, upstream of
the gene’s start codon but downstream of the gene’s predicted start
sites, CpG island, and 5-HTTLPR locus. Methylation -values of
o0.2 and 40.8 have previously been characterized as unmethylated
and methylated, respectively.[28]
PYROSEQUENCING VALIDATION
We used locus-specific pyrosequencing to validate methylation
data at cg22584138. Pyrosequencing assays were designed and
implemented by EpigenDx (Worcester, MA). We observed a highly
significant (r 5 .45, Po.001) correlation between the methylation
value at the same locus in the the pyrosequencing assay as from the
Illumina Beadchip, based on data from 85 of the original 100
individuals tested in the microarray analysis.
GENOTYPING
Samples were initially genotyped using the method described for
genotyping the SLC6A4 promoter polymorphism in Gelertner
et al.[31] Genotyping in this initial phase was performed using
Qiagenr’s Taq PCR Core Kit and associated protocols, along with
the cycling parameters of 941C initial at 2 min, followed by 33 cycles
of: 941C denature at 15 sec, 661C annealing temperature at 15 sec,
and 721C extension at 30 sec, and a final temperature at 721C at
5 min. PCR products were then visualized as short (S) or long (L) or
extra long (XL) alleles through visualization on a 2% agarose gel
stained with ethidium bromide. Amplification and visualization were
conducted at least twice in each individual in order to accurately call
each genotype. In order to further discern the functionally distinct La
and Lg alleles,[32] all samples from individuals with nonhomozygote
SS genotypes (n 5 87) were subjected to a second phase of analysis.
Samples in this second phase were amplified using Takara LA TaqTM
polymerase with the manufacturers’ buffer and dNTPs, again using
primers previously reported.[31] Thermocycling conditions included a
941C initial at 1 min, followed by 33 cycles of: 941C denature at
30 sec, 661C annealing temp at 30 sec, and 721C extension at 2 min,
and a final temperature at 721C for 5 min. Amplified products were
then subjected to restriction enzyme digestion with MspI.[33] Digested
products were then size fractionated and visualized using a 2%
agarose gel. For analyses, genotypes were grouped according to
functional classification as (1) SS, SLg, LgLg (low), (2) SLa, LgLa
(intermediate), and (3) LaLa (high). The function of XL is unknown;
therefore, one individual with LaXL was classified as ‘‘high’’ and
three individuals as LgXL were classified as low.
ANALYSIS
Data were analyzed using R v2.10.0 and SAS v9.2. DNA
methylation -values are continuous variables between 0 (completely
unmethylated) and 1 (completely methylated). Initially, variance in
methylation was assessed at each CpG site. Next, bivariate associa-
tions were assessed for methylation and PTSD for each of the
variables of interest. Main and interaction effects models were then
fitted to establish the relationships of the predictors to PTSD. In
order to ensure that our results were robust to quantitative and
qualitative assessments of PTSD, we modeled the PTSD outcome in
three ways. PTSD diagnosis based on the DSM-IV criteria was
modeled using logistic regression. PTSD severity is the aggregate of
intrusion, avoidance, and hyper-arousal symptom responses to ‘‘how
much bothered are you by this?’’ and was modeled using the general
linear model. The severity measure was log transformed for
normality. The number of symptoms is the sum of symptoms that
met the criteria of being present and bothered by it at least
‘‘moderately’’ was modeled using negative binomial regression.
Continuous variables, such as age, PBMC count, number of
traumatic events, and methylation -values, were centered to the
mean. All predictor variables were maintained in all the models for
consistency. Estimated coefficients were evaluated at a5 .05.
RESULTS
Initial results revealed substantial variation in
methylation -values at cg22584138, but not
cg05016953 (data not shown). Thus, statistical analyses
focused on cg22584138. Table 1 presents the descrip-
tive statistics and bivariate results for participants with
and without PTSD. Participants with PTSD reported
exposure to a significantly greater number of traumatic
events and were significantly more likely to have met
lifetime criteria for depression. We found no significant
association between SLC6A4 genotype or methylation
-values and PTSD. Methylation at cg22584138 was
significantly associated with female sex (P 5.04) and
number of traumatic events (P 5.04), but not age,
PBMCs, race, SES, smoking, depression, or SLC6A4
genotype (data not shown).
Table 2 presents results from the multivariable
logistic regression models for PTSD diagnosis.
In the main effects model, no significant associations
were observed. In the interaction model, the inter-
action term for methylation number of traumatic
events was significant (P 5.036). The interaction
model also provided a significantly improved fit
over the main effects model (w2(1) 5 5.649, P 5.02).
The interaction for SLC6A4 genotype number of
traumatic events was tested, but was not significant
(data not shown).
Table 3 presents results from the multivariable linear
regression models for PTSD symptom severity. In the
main effects model, sex, number of traumatic events,
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and lifetime depression were associated with greater
PTSD symptom severity. In the interaction model, the
interaction term for methylation number of trau-
matic events was significant (P 5.04). Based on the
adjusted R2, the interaction model also explained 3%
more of the variance in PTSD symptom severity than
the main effects model. The interaction for SLC6A4
genotypenumber of traumatic events was tested, but
was not significant (data not shown).
Table 4 presents results from the multivariable
binomial regression models for the number of PTSD
symptoms. In the main effects model, sex and number
of traumatic events was associated with more PTSD
symptoms. In the interaction model, the interaction
term for methylation number of traumatic events
was significant (P 5.018). The interaction model also
provided a significantly improved fit over the main
effects model (w2(1) 5 5.32, P 5.02). The interaction
for SLC6A4 genotype number of traumatic events
was tested, but was not significant (data not shown).
Figure 1 presents the interactions for the number
of traumatic events by methylation -value for the
predicted PTSD prevalence (Fig. 1A), number of
symptoms (Fig. 1B), and symptom severity (Fig. 1C).
Exposure to a greater number of traumatic events was
associated with increased risk of PTSD diagnosis,
TABLE 2. Effect of SLC6A4 methylation and number of traumatic events on risk of lifetime posttraumatic stress
disorder diagnosis
Main effects model Interaction model
2 Log L 5 93.268 2 Log L 5 87.619
b P 95% CI of b b P 95% CI of b
Intercept 2.7355 .0074 4.7366 0.7343 2.5973 .0113 4.6059 0.5886
Centered SLC6A4 methylation b-value 2.9250 .1878 7.2777 1.4278 0.3743 .8845 5.4253 4.6768
Number of traumatic events 0.1218 .1159 0.0300 0.2736 0.1638 .0669 0.0114 0.3391
Age 0.00329 .8489 0.0306 0.0372 0.00612 .7397 0.0300 0.0422
sex 0.5428 .3622 0.6247 1.7103 0.7154 .2500 0.5036 1.9344
African-American 0.1657 .8044 1.4775 1.1461 0.4456 .5290 1.8328 0.9416
Ever smoke 1.0813 .0792 0.1262 2.2888 1.0194 .1136 0.2435 2.2824
PBMC 0.0120 .6990 0.0726 0.0487 0.00530 .8644 0.0662 0.0556
Depression diagnosis 1.0446 .0597 0.0428 2.1320 1.1343 .0517 0.00854 2.2772
SLC6A4 sl genotype 0.3284 .6004 0.9005 1.5573 0.2726 .6752 1.0026 1.5479
SLC6A4 ss genotype 0.1116 .8864 1.6427 1.4194 0.1072 .8946 1.4781 1.6924
SLC6A4 methylation  number of traumatic events 1.5596 .0360 3.0170 0.1022
PBMC, peripheral blood mononuclear cells. ‘‘s’’ allele includes S and Lg; ‘‘l’’ allele includes La and XL. Continuous variables were centered to the mean.
TABLE 3. Effect of SLC6A4 methylation and number of traumatic events on risk of lifetime posttraumatic stress
disorder symptom severity
Main effects model Interaction model
Adjusted R2 5 0.2791 Adjusted R2 5 0.3051
b P 95% CI of b b P 95% CI of b
Intercept 3.17171 o.0001 2.90733 3.43608 3.19094 o.0001 2.93069 3.45120
Centered SLC6A4 methylation b-value 0.08024 .7899 0.67686 0.51638 0.11063 .7210 0.50296 0.72422
Number of traumatic events 0.04389 .0001 0.02192 0.06585 0.04848 o.0001 0.02647 0.07050
Age 0.00186 .4215 0.00642 0.00271 0.00158 .4873 0.00607 0.00291
sex 0.16367 .0439 0.00457 0.32277 0.18439 .0223 0.02691 0.34188
African-American 0.09231 .3226 0.09207 0.27669 0.07555 .4110 0.10621 0.25732
Ever smoke 0.11959 .1441 0.04165 0.28083 0.10766 .1812 0.05108 0.26641
PBMC 0.00700 .1331 0.00217 0.01617 0.00745 .1041 0.00157 0.01647
Depression diagnosis 0.18103 .0262 0.02197 0.34009 0.17302 .0305 0.01664 0.32940
SLC6A4 sl genotype 0.13842 .1144 0.03408 0.31091 0.13951 .1053 0.02988 0.30890
SLC6A4 ss genotype 0.15616 .1327 0.04831 0.36063 0.18129 .0783 0.02093 0.38350
SLC6A4 methylation  number of traumatic events 0.15546 .0404 0.30398 0.00694
PBMC, peripheral blood mononuclear cells. ‘‘s’’ allele includes S and Lg; ‘‘l’’ allele includes La and XL. Continuous variables were centered to the mean.
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greater number of symptoms, and greater severity of
symptoms at low levels of SLC6A4 methylation.
In contrast, at high levels of SLC6A4 methylation,
exposure to a greater number of traumatic events was
associated with resilience to developing PTSD.
DISCUSSION
We found that the number of traumatic events was
associated with PTSD diagnosis in this subsample of the
DNHS. However, this association was modified by
SLC6A4 methylation level at cg22584138, a CpG site
within the first intron of SLC6A4 located upstream of
the gene’s start codon, but downstream of transcription
start sites and the 5-HTTLPR VNTR locus. Specifi-
cally, number of traumatic events was strongly associated
with risk of PTSD, but only at lower methylation levels;
at higher methylation levels, individuals with more
traumatic events were protected from this disorder.
This interaction was observed whether the outcome
was PTSD diagnosis, symptom severity, or number of
symptoms. These results suggest that methylation levels
at SLC6A4 modify the effects of traumatic events in a
manner salient to PTSD etiology, offering a potential
molecular signature of increased risk for and resilience
to this disorder. In contrast to some prior studies,
neither the main effect of SLC6A4 genotype nor the
interaction of SLC6A4 genotype and number of trau-
matic events was related to PTSD.[7] Future work in this
longitudinal cohort will help to shed light on the extent
to which such epigenetic marks modify—or are modified
by—traumatic stress.
Notably, variation in methylation levels was observed
only for one of the two CpG sites examined (cg22584138).
This site differs in location from previous reports of
SLC6A4 methylation in relation to other stress-
related outcomes.[20–22] Our observations of disease-
associated methylation differences in the first intron of
the gene are not inconsistent with other reports of
methylation-mediated gene expression differences in
other diseases.[34] In addition, the role of noncoding
intronic DNA is coming under increasing scrutiny for
its role in regulating gene expression.[35] For these
reasons, our results offer a potentially novel site for
future investigations of stress-related outcomes invol-
ving the SCL6A4 locus as well as point to the potential
for targeting methylation-mediated gene regulation.
STUDY LIMITATIONS
Our study includes five limitations that should be
considered. First, the cross-sectional analyses reported
here leave us unable to determine whether the SLC6A4
methylation differences were a consequence of PTSD
or whether they are indicative of biologic vulnerabili-
ties that existed among the PTSD-affected before the
onset of their disorder. Ongoing work using samples
from this same longitudinal cohort should help to shed
light on this issue. Second, our necessary reliance
on peripheral tissues may limit the inferences that
can be drawn about SLC6A4 methylation in the brain.
Nevertheless, the use of blood-derived tissues for use
in assessing psychiatric disorders is increasingly being
recognized,[36] and a growing body of research is
documenting correspondence between brain- and
blood-derived gene expression signals.[37] Further-
more, recent work in nonhuman primates confirms
that SLC6A4 shows concordant methylation levels in
the blood and brain,[38] suggesting that results pre-
sented here may have relevance to the ‘‘target organ’’ of
PTSD. Third, data were unavailable to assess the
TABLE 4. Effect of SLC6A4 methylation and number of traumatic events on risk of lifetime number of posttraumatic
stress disorder symptoms
Main effects model Interaction model
2 Log L 5 540.0076 2 Log L 5 543.69
b P 95% CI of b b P 95% CI of b
Intercept 0.6600 .0406 0.0283 1.2916 0.6755 .0340 0.0509 1.3001
Centered SLC6A4 methylation b-value 0.0361 .9590 1.4097 1.3375 0.6208 .4017 0.8301 2.0718
Number of traumatic events 0.1012 .0001 0.0498 0.1526 0.1170 o.0001 0.0659 0.1682
Age 0.0027 .6290 0.0135 0.0082 0.0017 .7513 0.0123 0.0089
Sex 0.3853 .0407 0.0164 0.7542 0.4196 .0230 0.0578 0.7814
African-American 0.4105 .0764 0.0435 0.8644 0.3844 .0890 0.0586 0.8273
Ever smoke 0.1836 .3346 0.1894 0.5566 0.1649 .3707 0.1961 0.5258
PBMC 0.0110 .2867 0.0093 0.0314 0.0130 .2035 0.0070 0.0330
Depression diagnosis 0.3553 .0576 0.0115 0.7221 0.3737 .0411 0.0152 0.7321
SLC6A4 sl genotype 0.4177 .0426 0.0140 0.8215 0.4108 .0419 0.0150 0.8067
SLC6A4 ss genotype 0.3265 .1801 0.1509 0.8039 0.3803 .1128 0.0897 0.8503
SLC6A4 methylation  number of traumatic events 0.4122 .0184 0.7548 0.0695
PBMC, peripheral blood mononuclear cells. ‘‘s’’ allele includes S and Lg; ‘‘l’’ allele includes La and XL. Continuous variables were centered to the mean.
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correlation between methylation and gene expression
in the same individuals for this locus, limiting our
ability to infer the proximal phenotypic impact (i.e.
gene expression differences) of the observed interac-
tion. Fourth, PTSD in this sample, as in the general
population, is highly comorbid with depression. We
attempted to address this issue by adjusting for
depression in our models. However, due to our small
sample size, we did not have power to test whether our
findings were consistent among those with PTSD
along versus those with PTSD and depression. Finally,
our sample size (n 5 100) is small. Nonetheless, we did
observe statistically significant results across PTSD
diagnosis, number of symptoms, and symptom severity,
suggesting that the findings reported here are robust.
Future work in other independent cohorts is warranted
to confirm these initial findings.
CONCLUSIONS
PTSD becomes chronic in over half the individuals
who develop the disorder.[39] Despite three decades of
research, we still have limited understanding of why,
among those exposed to trauma, only some individuals
will develop PTSD. Our findings suggest that gene-
specific methylation patterns may offer potential mole-
cular signatures of increased risk for and resilience to
this disorder. Future work in our longitudinal cohort
will help to shed light on the mechanisms underlying
our observations and the extent to which such epigenetic
marks modify—or are modified by—traumatic stress.
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